文献速递生殖医学妇科

乳腺癌年轻女性紧急生育力保存中GnRH拮抗剂方案控制性卵巢刺激的疗效与安全性:瑞典全国多中心前瞻性研究

Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer-a prospective nationwide Swedish multicenter study.
PubMed 文献 · Hum Reprod · 2020-01-01

该前瞻性全国多中心研究纳入610名接受生育力咨询的乳腺癌女性,其中401人选择控制性卵巢刺激(COS)。来曲唑方案与常规方案、随机启动与常规启动的获卵数和冻存胚胎数相似;来曲唑方案中使用GnRHa触发较hCG触发获卵数及冻存胚胎数更高。接受COS者与未接受者总生存相似。

要点

  • 来曲唑方案与常规COS的获卵数和冻存胚胎数相似。
  • 随机启动与常规启动COS的获卵数和冻存胚胎数相似。
  • 来曲唑方案中GnRHa触发较hCG触发获卵数及冻存胚胎数更高。

核心结论

  • 乳腺癌女性COS生育力保存中来曲唑方案和随机启动与常规COS同等有效,接受COS与未接受者总生存相似。

研究设计与样本

  • 前瞻性全国多中心研究,纳入1995年1月1日至2017年6月30日在瑞典6个生育力保存区域项目咨询的610名乳腺癌女性,其中401人接受COS。

主要发现

  • 来曲唑与无来曲唑的冻存卵母数均值分别为9.7与10,冻存胚胎数均值分别为4.0与5.3。
  • 随机启动与常规启动COS的冻存卵母数均值分别为9.0与10.6,冻存胚胎数均值均为4.8。
  • 来曲唑COS中GnRHa触发较hCG触发获卵数更高(P < 0.05),冻存胚胎数更高(P < 0.005)。
  • 99名治疗后返回生育门诊的女性中,32人进行卵母或胚胎解冻,其中10人获得活产。
  • 接受COS与未接受COS女性的全因生存相似,两组间无差异。

临床怎么用

  • 乳腺癌女性紧急生育力保存可考虑来曲唑方案或随机启动COS,疗效与常规方案相当。
  • 来曲唑方案中可优先选用GnRHa触发以增加获卵数和冻存胚胎数。

局限性

  • 生育力保存咨询和COS规划时并非所有女性均已知肿瘤特征和雌激素受体(ER)状态,来曲唑方案同时用于雌激素敏感和非敏感乳腺癌。
  • 因ER状态和肿瘤特征数据不可及,未进行后续混杂因素调整,但这些参数不影响COS生育力保存的实施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: How efficacious and safe are the current approaches to controlled ovarian stimulation (COS) aimed at fertility preservation (FP) in women with breast cancer (BC)? SUMMARY ANSWER: In women with BC undergoing COS aiming at egg/embryo cryopreservation, letrozole-based protocols and those randomly started were equally effective compared with conventional COS, and the overall survival was similar between the women that proceeded to FP and those who did not. WHAT IS KNOWN ALREADY: Cryopreservation of oocytes and embryos is an established method for FP in women with BC. Recent improvements to COS protocols include concomitant use of letrozole, random-cycle start day of stimulation and the use of GnRHa for the egg maturation trigger. To date, limited sample size of the available studies has not allowed investigation of differences in the efficacy of the different approaches to COS for FP in this patient population. STUDY DESIGN, SIZE, DURATION: A prospective multicenter study with national coverage including 610 women with BC counseled between 1 January 1995 and 30 June 2017 at six Swedish FP regional programs. PARTICIPANTS/MATERIALS, SETTING, METHODS: After counseling, 401 women elected to undergo COS. Treatments differed in the use or not of concomitant letrozole, a conventional or random-cycle day COS initiation and the use of hCG versus GnRHa trigger for oocyte maturation. Numbers of cryopreserved oocytes and embryos were defined as primary outcome. Pregnancy attempts, reproductive outcomes and long-term survival, investigated by the linking of individuals of the cohort to the total population register of the Swedish Tax Agency (up to 25 November 2018), were evaluated. MAIN RESULTS AND THE ROLE OF CHANCE: Using letrozole or not resulted in similar numbers of oocytes and embryos cryopreserved (meanoocytes = 9.7 versus 10 and meanembryos 4.0 versus 5.3, respectively), similar to COS with random versus conventional start (meanoocytes 9.0 versus 10.6 and meanembryos 4.8 versus 4.8). In COS with letrozole, a GnRHa trigger was associated with a higher number of oocytes retrieved (P < 0.05) and embryos cryopreserved (P < 0.005), compared with conventional hCG trigger. Of 99 women who returned to fertility clinics after cancer treatment, 32 proceeded to thawing of oocytes or embryos and 10 of them had live births. The all-cause survival between the women that underwent COS and those who did not was similar and did not differ between the two groups. LIMITATIONS, REASONS FOR CAUTION: Data on tumor characteristics and estrogen receptor (ER) status were not known for all women at the time of FP counseling and planning of COS, thus protocols with letrozole have been used for both estrogen-sensitive and non-estrogen-sensitive BC. For the same reason, subsequent adjustment for ERs in the BC or tumor characteristics as potential confounders were not performed as these parameters were not available and did not influence the provision of FP through COS. WIDER IMPLICATIONS OF THE FINDINGS: The results of our study support the premise that recently introduced potential improvements to COS protocols for FP in women with BC are efficacious and safe. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by research grants from the Swedish Cancer Society, the Stockholm County Council, the Percy Falk Stiftelsen, Radiumhemmets Forskningsfonder, The Swedish Breast Cancer Association and Karolinska Institutet to K.A.R.W. J.B. reports grants from Amgen, AstraZeneca, Pfizer, Roche, Sanofi-Aventis and Merck, outside the submitted work, and payment from UpToDate to Asklepios Medicine HB for a chapter on BC prediction and prognostication. All the other authors have no competing interests to report.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Marklund A, Eloranta S, Wikander I, et al. Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer-a prospective nationwide Swedish multicenter study. Hum Reprod. 2020. PMID: 32313940. doi:10.1093/humrep/deaa029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。